**Core tip:** The conventional guidelines suggest the surgeons to obtain an extensive resection margin during surgery for gastric cancer. The objective of this study was to investigate the influence of the proximal resection margin (PRM) distance on the oncologic outcomes of advanced gastric cancer patients, thus to prove the safety of the PRM distance shorter than the conventional literatures suggest. The length of the PRM did not affect the prognosis of patients who underwent a curative gastrectomy for advanced gastric cancer.

INTRODUCTION
============

Although the worldwide gastric cancer incidence has been declining over the past few decades, gastric cancer remains the third leading cause of cancer mortality\[[@B1]-[@B3]\] and surgery is still the mainstay curative treatment for gastric cancer patients\[[@B4]\]. While radical surgery with adequate resection of the stomach and lymph nodes is the prime focus of treatment, quality of life after surgery has been receiving increased attention due to improvements in the postoperative survival of gastric cancer patients. Several studies have revealed that subtotal gastrectomy leads to better nutrition and quality of life after surgery than total gastrectomy (TG)\[[@B5],[@B6]\], and a recent report showed the relationship between the remnant volume of the stomach and nutritional status after surgery\[[@B7]\]. Thus, surgeons should consider these factors when determining the optimal extent of resection.

Bozzetti et al\[[@B8]\] reported that a proximal resection margin (PRM) of at least 6 cm should be obtained for tumors invading the serosa to ensure an infiltration-free margin. However, this was published back in 1982 and may not accurately reflect the current state of gastric cancer treatment where values such as function preservation, nutrition, and quality of life are emphasized. The 2014 Japanese gastric cancer treatment guidelines (Version 4) suggest that a gross margin of at least 3 cm should be obtained for T2 or deeper tumors with Bormann type 1 or 2, and 5 cm should be obtained for Bormann type 3 or 4 tumors\[[@B9]\]. The National Comprehensive Cancer Network recommends a PRM of \> 4 cm for a safe microscopic margin\[[@B10]\]. These guidelines do not specify the clinical studies, making it difficult to assess the reliability of the suggested PRMs.

In 2014, it was reported that as long as negative margins were obtained by intraoperative frozen-section examination, PRM is not related to patient survival or local recurrence\[[@B11]\]. However, a 2017 study revealed that PRM is an independent prognostic factor for the overall survival (OS) of gastric cancer patients and a PRM of at least 2.1 cm should be obtained\[[@B12]\]. Several other studies have examined the relationship between the PRM and the prognosis of patients with gastric cancer, but the results were inconsistent\[[@B13]-[@B18]\], particularly for patients with advanced gastric cancer (AGC).

This study is based on extensive retrospectively collected data and aims to investigate the relationship between PRM and the recurrence-free survival (RFS) or OS after surgery and thus determine the optimal PRM for patients with AGC.

MATERIALS AND METHODS
=====================

Patients
--------

Between June 2004 and December 2007, 1518 patients in total underwent total or distal gastrectomy (DG) with curative intent for AGC at the Division of Stomach Surgery in Asan Medical Center. Patients with stage IV AGC or evident gross residual tumor were observed intraoperatively and those who underwent palliative gastrectomy were not included in the study. We excluded gastroesophageal junction cancer (Siewert I or II) patients, patients with a history of previous stomach surgery, patients who underwent neoadjuvant chemotherapy and patients whose pathologic report confirmed fewer than 15 lymph nodes retrieved. Cases in which grossly positive resection margins were observed, and those where the final biopsy reports confirmed a positive resection margin were excluded. We also excluded cases without data for PRM.

To evaluate patient characteristics, we collected data on the sex, age, preoperative body mass index (BMI), history of previous operations on the stomach, medical history of hypertension (HTN), diabetes mellitus (DM), American Society of Anesthesiologists (ASA) score, history of smoking, preoperative value of CEA, CA 19-9 and CA 72-4, tumor location, type of surgery (TG or DG), and type of recon-struction. Clinicopathologic outcomes included the Borrmann classification of the tumor, the number of synchronous tumors in the stomach, tumor size, depth of invasion, number of lymph nodes collected (CLN), number of positive lymph nodes (PLN), histology according to differentiation, status of lymphovascular invasion (LVi) and Perineural invasion (PNi), distance of the tumor from the PRM and distal resection margin (DRM), TNM stage based on the American Joint Committee on Cancer (AJCC) staging Manual 7^th^ edition, recurrence status, and survival.

The extent of resection was determined according to the surgeon's preference, primarily based on the Japanese gastric cancer treatment guidelines. The tumor location was defined according to equally divided sections for the upper-third, middle-third, and lower-third of the stomach. For multiple cancers, the location was defined based on the most proximal tumor. The distances of the PRM and DRM were defined as the shortest distance from the most proximal or distal end to each resection line, measured on formalin-fixed surgical specimens by pathologists. Recurrence was classified as locoregional (anastomosis site, remnant stomach, gastric bed, regional lymph nodes, adjacent organ, or paraaortic lymph node), hematogenous (distant organs), peritoneal (peritoneal seeding or Krukenberg's tumor), distant lymph nodes (extra-abdominal lymph nodes), and mixed. The main patterns of recurrence were determined based on the site at the time of diagnosis.

This study was approved by the Institutional Review Board of Asan Medical Center and the University of Ulsan College of Medicine (No. 2019-1036).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS version 21.0 (SPSS, Inc., Chicago, IL, United States). To analyze the demographics and clinicopathologic features depending on different PRM categories, one-way ANOVA and Fisher's exact test were used for continuous and categorical variables, respectively. Kaplan-Meier survival analysis and Cox proportional hazard analysis were performed to assess the impact of PRM on RFS and OS. Any *P* value \< 0.05 was considered statistically significant. The study was reviewed by a biomedical statistician from Department of medical statistics, University of Ulsan College of Medicine.

RESULTS
=======

Table [1](#T1){ref-type="table"} summarizes the patients' baseline demographics and clinicopathologic characteristics. There were 859 patients who underwent DG and 659 patients who underwent TG. The median age at the time of operation was 60 and 57 in the two groups, respectively. In the DG group, there were 626 patients (72.9%) with tumors located in the lower third of the stomach. In the TG group, 586 (88.9%) had cancer in the upper or middle third of the stomach. After DG, anastomosis was performed using the Billroth I reconstruction method for 71.0% of patients, Billroth II for 15.9% and Roux-en-Y gastrojejunostomy (RYGJ) for 13.0%.

###### 

The basic demographics and clinicopathologic characteristics of patients who underwent distal and total gastrectomy with curative intent for gastric adenocarcinoma, *n* (%)

  **Variables**                   **Distal gastrectomy (*n* = 859)**   **Total gastrectomy (*n* = 659)**
  ------------------------------- ------------------------------------ -----------------------------------
  Age (yr; median) at operation   60 (23-87)                           57 (22-86)
  Sex                                                                  
  Male                            603 (70.2)                           441 (66.9)
  Female                          256 (29.8)                           218 (33.1)
  BMI (kg/m^2^, median)           23.2 (16.0-36.2)                     23.4 (13.4-36.0)
  ASA                                                                  
  1                               246 (28.6)                           213 (32.3)
  2                               571 (66.5)                           427 (64.8)
  3                               39 (4.5)                             17 (2.6)
  4                               3 (0.3)                              2 (0.3)
  Tumor location                                                       
  Upper 1/3                       8 (0.9)                              266 (40.4)
  Middle 1/3                      225 (26.2)                           320 (48.6)
  Lower 1/3                       626 (72.9)                           73 (11.1)
  Reconstruction                                                       
  Billroth I                      610 (71.0)                           
  Billroth II                     137 (15.9)                           
  RYGJ                            112 (13.0)                           
  RY                                                                   659 (100.0)
  Bormann classification                                               
  I                               14 (1.6)                             14 (2.1)
  II                              162 (18.9)                           66 (10.0)
  III                             660 (76.8)                           499 (75.7)
  IV                              23 (2.7)                             80 (12.1)
  Tumor size (cm, median)         5.0 (0.8-18)                         6.0 (0.7-24)
  CLN                             27 (15-75)                           30 (15-106)
  PLN                             2 (0-49)                             3 (0-101)
  T stage                                                              
  T2                              288 (33.5)                           110 (16.7)
  T3                              370 (43.1)                           310 (47.0)
  T4a                             195 (22.7)                           226 (34.3)
  T4b                             6 (0.7)                              13 (2.0)
  N stage                                                              
  N0                              308 (35.9)                           203 (30.8)
  N1                              181 (21.1)                           110 (16.7)
  N2                              173 (20.1)                           128 (19.4)
  N3a                             159 (18.5)                           133 (20.2)
  N3b                             38 (4.4)                             85 (12.9)
  AJCC stage                                                           
  Stage I                         155 (18.0)                           66 (10.0)
  Stage II                        336 (39.1)                           235 (35.7)
  Stage III                       368 (42.8)                           358 (54.3)
  PRM (cm; median)                4.8 (0.3-17)                         3.5 (0.1-18.5)
  DRM (cm; median)                3.2 (0.2-19)                         9.4 (0.3-27)
  Histology                                                            
  Differentiated                  351 (40.9)                           192 (29.1)
  Undifferentiated                508 (59.1)                           467 (70.9)
  Lymphovascular invasion         413 (48.1)                           360 (54.6)
  Perineural invasion             368 (42.8)                           344 (52.2)
  Recurrence                      220 (25.6)                           251 (38.1)
  Locoregional recurrence         60                                   41
  Hematogenous metastasis         74                                   83
  Extra-abdominal LN metastasis   2                                    1
  Peritoneal metastasis           74                                   1
  Mixed                           10                                   17

RYGJ: Roux-en-Y gastrojejunostomy; RY: Roux-en-Y esophagojejunostomy; CLN: Total number of collected lymph nodes; PLN: Total number of positive lymph nodes; PRM: Proximal resection margin; DRM: Distal resection margin; AJCC: American Joint Committee on Cancer.

The median PRM distance was 4.8 cm and 3.5 cm in the DG and TG groups, respectively. There were 220 (25.6%) and 251 (38.1%) cases of recurrence during the follow-up period of 59 (0-127) and 58 (0-129) months in each group.

Patient cohorts in the DG and TG groups were subdivided into different groups according to the length of the PRM: ≤ 1.0 cm, 1.1-3.0 cm, 3.1-5.0 cm and \> 5.0 cm. Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} present the clinicopathologic factors in the different PRM subgroups. In both the DG and TG groups, there were no significant differences in age, sex, T stage, or N stage according to the PRM distance. Among patients who underwent DG, the tumor location (*P* \< 0.001), reconstruction type (*P* = 0.004) and tumor size (*P* = 0.004) differed between the PRM subgroups. Additionally, there were more undifferentiated tumors (*P* = 0.023) and perineural invasion (*P* = 0.010) in the PRM ≤ 1 cm subgroup. In the TG group, there were statistical differences in the tumor location (*P* \< 0.001), tumor size (*P* \< 0.001), proportion of linitis plastica (*P* \< 0.001), and perineural invasion (*P* = 0.002) between the PRM subgroups. There were no significant differences in the recurrence rate or local recurrence rate according to the PRM distance in either the DG or TG group.

###### 

Clinicopathologic factors depending on the distance from the proximal resection margin in patients who underwent curative distal gastrectomy, *n* (%)

  **Variables**                                           **PRM (cm)**   ***P* value**                             
  ------------------------------------------------------- -------------- --------------- ------------ ------------ ----------
  Age (yr)[1](#T2FN1){ref-type="table-fn"} at operation   59.7 ± 3.4     57.2 ± 1.0      58.2 ± 0.7   59.0 ± 0.6   0.416
  Sex                                                                                                              0.279
  Male                                                    9 (52.9)       116 (68.2)      199 (69.3)   279 (72.5)   
  Female                                                  8 (47.1)       54 (31.8)       88 (30.7)    106 (27.5)   
  Tumor location                                                                                                   \< 0.001
  Upper 1/3                                               1 (5.9)        3 (1.8)         3 (1.0)      1 (0.3)      
  Middle 1/3                                              9 (52.9)       74 (43.5)       86 (30.0)    56 (14.5)    
  Lower 1/3                                               7 (41.2)       93 (54.7)       198 (69.0)   328 (85.2)   
  Reconstruction                                                                                                   0.004
  Billroth I                                              12 (70.6)      101 (59.4)      218 (76.0)   279 (72.5)   
  Billroth II                                             3 (17.6)       32 (18.8)       38 (13.2)    64 (16.6)    
  RYGJ                                                    2 (11.8)       37 (21.8)       31 (10.8)    42 (10.9)    
  Borrmann type IV                                        1 (5.9)        6 (3.5)         7 (2.4)      9 (2.3)      0.461
  Tumor size (cm)[1](#T2FN1){ref-type="table-fn"}         6.5 ± 0.8      5.8 ± 0.2       5.3 ± 0.1    5.2 ± 0.1    0.004
  T stage                                                                                                          0.768
  T2                                                      5 (29.4)       56 (32.9)       89 (31.0)    138 (35.8)   
  T3                                                      7 (41.2)       75 (44.1)       123 (42.9)   165 (42.9)   
  T4                                                      5 (29.4)       39 (22.9)       75 (26.1)    82 (21.3)    
  CLN[1](#T2FN1){ref-type="table-fn"}                     26.6 ± 2.0     29.3 ± 0.8      29.4 ± 0.6   28.8 ± 0.5   0.612
  N stage                                                                                                          0.971
  N0                                                      5 (29.4)       61 (35.9)       101 (35.2)   141 (36.6)   
  N1                                                      2 (11.8)       36 (21.2)       63 (22.0)    80 (20.8)    
  N2                                                      4 (23.5)       36 (21.2)       55 (19.2)    78 (20.3)    
  N3                                                      6 (35.3)       37 (21.8)       68 (23.7)    86 (22.3)    
  AJCC stage                                                                                                       0.551
  Stage I                                                 4 (23.5)       31 (18.2)       52 (18.1)    68 (17.7)    
  Stage II                                                3 (17.6)       65 (38.2)       108 (37.6)   160 (41.6)   
  Stage III                                               10 (58.8)      74 (43.5)       127 (44.3)   157 (40.8)   
  Differentiation                                                                                                  0.023
  Differentiated                                          4 (23.5)       64 (37.6)       105 (36.6)   178 (46.2)   
  Undifferentiated                                        13 (76.5)      106 (62.4)      182 (63.4)   207 (53.8)   
  LVi                                                     8 (47.1)       75 (44.1)       142 (49.5)   188 (48.8)   0.706
  PNi                                                     9 (52.9)       80 (47.1)       138 (48.1)   141 (36.6)   0.010
  Recurrence                                              4 (23.5)       52 (30.6)       69 (24.0)    95 (24.7)    0.765
  Local recurrence                                        1 (5.9)        11 (6.5)        24 (8.4)     24 (6.2)     0.727

mean ± standard error. PRM: Proximal resection margin; RYGJ: Roux-en-Y gastrojejunostomy; CLN: Total number of collected lymph nodes; AJCC: American Joint Committee on Cancer; LVi: Lymphovascular invasion; PNi: Perineural invasion.

###### 

Clinicopathologic factors depending on the distance from the proximal resection margin in patients who underwent curative total gastrectomy, *n* (%)

  **Variables**                                           **PRM (cm)**   ***P* value**                             
  ------------------------------------------------------- -------------- --------------- ------------ ------------ ----------
  Age (yr)[1](#T3FN1){ref-type="table-fn"} at operation   57.1 ± 1.2     55.0 ± 0.9      54.6 ± 0.9   56.3 ± 0.9   0.330
  Sex                                                                                                              0.364
  Male                                                    64 (71.1)      135 (64.6)      92 (63.0)    150 (70.1)   
  Female                                                  26 (38.9)      74 (35.4)       54 (37.0)    64 (29.9)    
  Tumor location                                                                                                   \< 0.001
  Upper 1/3                                               81 (90.0)      127 (60.8)      32 (21.9)    26 (12.1)    
  Middle 1/3                                              8 (8.9)        75 (35.9)       103 (70.5)   134 (62.6)   
  Lower 1/3                                               1 (1.1)        7 (3.3)         11 (7.5)     54 (25.2)    
  Borrmann type IV                                        17 (18.9)      37 (17.7)       14 (9.6)     12 (5.6)     \< 0.001
  Tumor size (cm)[1](#T3FN1){ref-type="table-fn"}         8.1 ± 0.5      7.6 ± 0.3       7.0 ± 0.3    5.9 ± 0.2    \< 0.001
  T stage                                                                                                          0.873
  T2                                                      14 (15.6)      30 (14.4)       24 (16.4)    42 (19.6)    
  T3                                                      44 (48.9)      100 (47.8)      67 (45.9)    99 (46.3)    
  T4                                                      32 (35.6)      79 (37.8)       55 (37.7)    73 (34.1)    
  CLN[1](#T3FN1){ref-type="table-fn"}                     30.7 ± 1.1     33.1 ± 1.0      32.2 ± 1.0   31.0 ± 0.7   0.216
  N stage                                                                                                          0.495
  N0                                                      23 (25.6)      74 (35.4)       47 (32.2)    59 (27.6)    
  N1                                                      14 (15.6)      35 (16.7)       21 (14.4)    40 (18.7)    
  N2                                                      15 (16.7)      41 (19.6)       30 (20.5)    42 (19.6)    
  N3                                                      38 (42.2)      59 (28.2)       48 (32.9)    73 (34.1)    
  AJCC stage                                                                                                       0.587
  Stage I                                                 8 (8.9)        19 (9.1)        14 (9.6)     25 (11.7)    
  Stage II                                                29 (32.2)      85 (40.7)       53 (35.3)    68 (31.8)    
  Stage III                                               53 (58.9)      105 (50.2)      79 (54.1)    121 (56.5)   
  Differentiation                                                                                                  0.082
  Differentiated                                          29 (32.2)      55 (26.3)       34 (23.3)    74 (34.6)    
  Undifferentiated                                        61 (67.8)      154 (73.7)      112 (76.7)   140 (65.4)   
  LVi                                                     57 (63.3)      108 (51.7)      75 (51.4)    120 (56.1)   0.231
  PNi                                                     54 (60.0)      101 (48.3)      92 (63.0)    97 (45.3)    0.002
  Recurrence                                              44 (48.9)      80 (38.3)       48 (32.9)    79 (36.9)    0.648
  Local recurrence                                        8 (8.9)        10 (4.6)        11 (6.9)     14 (6.2)     0.637

mean ± standard error. PRM: Proximal resection margin; RYGJ: Roux-en-Y gastrojejunostomy; CLN: Total number of collected lymph nodes; AJCC: American Joint Committee on Cancer; LVi: Lymphovascular invasion; PNi: Perineural invasion.

Kaplan-Meier analysis was performed to assess the impact of PRM distance on RFS and OS. In the DG group, the mean RFS was 83.8, 90.9, 96.0, and 94.9 mo with a five-year RFS of 35.3%, 41.8%, 47.0%, and 41.0% in the PRM ≤ 1 cm, 1.1-3.0 cm, 3.1-5.0 cm, and \> 5 cm subgroups, respectively. In the TG group, the mean RFS was 73.8, 78.5, 88.3, and 83.7 mo with a five-year RFS of 42.2%, 33.0%, 45.9%, and 39.3%, respectively. Neither the DG nor TG group showed statistical differences in either RFS or OS according to the PRM distances (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![Correlation of overall survival (A) and recurrence-free survival (B) with the distance of proximal resection margin in patients who underwent distal gastrectomy. Kaplan-Meier method was used to analyze OS and RFS according to the distance of PRM. There were no significant differences between the PRM subgroups. OS: Overall survival; RFS: Recurrence-free survival; PRM: Proximal resection margin.](WJG-26-2232-g001){#F1}

![Correlation of overall survival (A) and recurrence-free survival (B) with the distance of proximal resection margin in patients who underwent total gastrectomy. The Kaplan-Meier method was used to analyze OS and RFS according to the distance of PRM. There were no significant differences between the PRM subgroups. OS: Overall survival; RFS: Recurrence-free survival; PRM: Proximal resection margin.](WJG-26-2232-g002){#F2}

Univariate and multivariate analyses were performed to investigate the impact of the PRM distance and other factors on OS (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}) and RFS (Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}) using the Cox proportional hazard model. Variable selection for multivariate analysis was done using the backward elimination method with a likelihood ratio test. This revealed that among patients who underwent DG, a higher T stage (T3; *P =* 0.003, T4; *P* \< 0.001) and N stage (N2, N3; *P* \< 0.001) were associated with worse RFS. Other risk factors included older age (*P* = 0.012) and reconstruction type; Billroth II (*P* = 0.016) and RYGJ (*P* = 0.003) reconstructions resulted in worse RFS than Billroth I reconstruction (Table [6](#T6){ref-type="table"}). In the TG group, higher T stage (T4; *P* = 0.014) and N stage (N2; *P* = 0.001, N3; *P* \< 0.001) were risk factors associated with RFS. Older age (*P =* 0.032), linitis plastica (*P* \< 0.001) and the presence of lymphovascular invasion (*P* = 0.013) were also associated with worse RFS (Table [7](#T7){ref-type="table"}). However, neither group showed a significant difference in either RFS or OS according to the distance of the PRM.

###### 

Analysis of the risk factors associated with overall survival in patients who underwent distal gastrectomy using the Cox proportional hazard model

                           **Univariate**     **Multivariate**                      
  ------------------------ ------------------ ------------------ ------------------ ----------
  Age                      1.04 (1.03-1.05)   \< 0.001           1.04 (1.03-1.05)   \< 0.001
  Female sex               0.89 (0.69-1.15)   0.367                                 
  BMI                      0.94 (0.90-0.98)   0.002                                 
  Tumor location                                                                    
  Upper 1/3                Ref.                                                     
  Mid 1/3                  3.11 (0.43-22.4)   0.260                                 
  Lower 1/3                3.54 (0.50-25.2)   0.208                                 
  Reconstruction                                                                    
  Billroth I               Ref.                                  Ref.               
  Billroth II              1.66 (1.26-2.20)   \< 0.001           1.40 (1.04-1.87)   0.025
  RYGJ                     1.34 (0.96-1.86)   0.083              1.45 (1.04-2.03)   0.030
  Tumor size               1.11 (1.06-1.16)   \< 0.001                              
  Borrmann type IV         0.96 (0.48-1.94)   0.914                                 
  CLN                      0.99 (0.98-1.00)   0.045              0.99 (0.98-1.00)   0.034
  T stage                                                                           
  T2                       Ref.                                  Ref.               
  T3                       1.36 (1.01-1.83)   0.044              1.08 (0.79-1.48)   0.612
  T4                       3.02 (2.24-4.06)   \< 0.001           1.90 (1.38-2.62)   \< 0.001
  N stage                                                                           
  N0                       Ref.                                  Ref.               
  N1                       1.07 (0.73-1.56)   0.739              0.92 (0.63-1.36)   0.686
  N2                       2.33 (1.67-3.25)   \< 0.001           2.06 (1.46-2.90)   \< 0.001
  N3                       3.74 (2.77-5.05)   \< 0.001           3.10 (2.25-4.28)   \< 0.001
  Diffuse type histology   1.00 (0.79-1.25)   0.967                                 
  LVi                      1.82 (1.44-2.29)   \< 0.001                              
  PNi                      1.32 (1.06-1.66)   0.015                                 
  PRM (cm)                                                                          
  0-1.0                    Ref.                                                     
  1.1-3.0                  0.57 (0.27-1.19)   0.134                                 
  3.1-5.0                  0.59 (0.29-1.23)   0.162                                 
  \> 5.0                   0.61 (0.30-1.25)   0.175                                 

PRM: Proximal resection margin; RYGJ: Roux-en-Y gastrojejunostomy; CLN: Total number of collected lymph nodes; LVi: Lymphovascular invasion; PNi: Perineural invasion.

###### 

Analysis of the risk factors associated with overall survival in patients who underwent total gastrectomy using the Cox proportional hazard model

                           **Univariate**     **Multivariate**                      
  ------------------------ ------------------ ------------------ ------------------ ----------
  Age                      1.02 (1.01-1.03)   \< 0.001           1.03 (1.02-1.04)   \< 0.001
  Female sex               1.03 (0.81-1.30)   0.834                                 
  BMI                      0.95 (0.92-0.99)   0.009                                 
  Tumor location                                                                    
  Upper 1/3                Ref.                                                     
  Mid 1/3                  0.76 (0.60-0.95)   0.018                                 
  Lower 1/3                0.94 (0.65-1.35)   0.723                                 
  Tumor size               1.09 (1.07-1.12)   \< 0.001                              
  Borrmann type IV         2.21 (1.66-2.94)   \< 0.001           1.93 (1.43-2.60)   \< 0.001
  CLN                      1.00 (0.99-1.01)   0.548              0.99 (0.98-1.00)   0.035
  T stage                                                                           
  T2                       Ref.                                  Ref.               
  T3                       1.67 (1.14-2.45)   0.008              1.21 (0.81-1.81)   0.352
  T4                       3.24 (2.22-4.72)   \< 0.001           1.85 (1.22-2.79)   0.004
  N stage                                                                           
  N0                       Ref.                                  Ref.               
  N1                       1.11 (0.74-1.68)   0.617              1.03 (0.67-1.57)   0.900
  N2                       1.73 (1.21-2.46)   0.003              1.48 (1.01-2.18)   0.045
  N3                       3.87 (2.88-5.19)   \< 0.001           2.81 (1.98-3.98)   \< 0.001
  Diffuse type histology   1.23 (0.96-1.58)   0.103                                 
  LVi                      2.09 (1.65-2.64)   \< 0.001           1.43 (1.10-1.86)   0.008
  PNi                      1.60 (1.27-2.00)   \< 0.001                              
  PRM (cm)                                                                          
  0-1.0                    Ref.                                                     
  1.1-3.0                  0.80 (0.57-1.10)   0.164                                 
  3.1-5.0                  0.65 (0.45-0.93)   0.019                                 
  \> 5.0                   0.81 (0.58-1.12)   0.202                                 

PRM: Proximal resection margin; RYGJ: Roux-en-Y gastrojejunostomy; CLN: Total number of collected lymph nodes; LVi: Lymphovascular invasion; PNi: Perineural invasion.

###### 

Analysis of the risk factors associated with recurrence-free survival in patients who underwent distal gastrectomy using the Cox proportional hazard model

                           **Univariate**      **Multivariate**                      
  ------------------------ ------------------- ------------------ ------------------ ----------
  Age                      1.02 (1.00-1.03)    0.011              1.02 (1.00-1.03)   0.012
  Female sex               0.93 (0.69-1.25)    0.636                                 
  BMI                      0.96 (0.92-1.00)    0.068                                 
  Tumor location                                                                     
  Upper 1/3                Ref.                                                      
  Mid 1/3                  2.32 (0.32-16.77)   0.403                                 
  Lower 1/3                2.35 (0.33-16.76)   0.395                                 
  Reconstruction                                                                     
  Billroth I               Ref.                                   Ref.               
  Billroth II              1.90 (1.37-2.64)    \< 0.001           1.50 (1.08-2.10)   0.016
  RYGJ                     1.87 (1.31-2.67)    0.001              1.72 (1.20-2.47)   0.003
  Tumor size               1.16 (1.10-1.21)    \< 0.001                              
  Borrmann type IV         1.04 (0.46-2.33)    0.931                                 
  CLN                      1.00 (0.99-1.01)    0.91                                  
  T stage                                                                            
  T2                       Ref.                                   Ref.               
  T3                       2.61 (1.72-3.96)    \< 0.001           1.92 (1.25-2.95)   0.003
  T4                       6.17 (4.08-9.34)    \< 0.001           3.42 (2.21-5.31)   \< 0.001
  N stage                                                                            
  N0                       Ref.                                   Ref.               
  N1                       1.23 (0.75-2.03)    0.415              1.03 (0.62-1.70)   0.92
  N2                       3.42 (2.26-5.19)    \< 0.001           2.55 (1.67-3.89)   \< 0.001
  N3                       5.75 (3.92-8.42)    \< 0.001           3.88 (2.59-5.80)   \< 0.001
  Diffuse type histology   1.19 (0.91-1.57)    0.206              1.05 (0.79-1.39)   0.758
  LVi                      2.29 (1.73-3.02)    \< 0.001                              
  PNi                      1.63 (1.25-2.12)    \< 0.001                              
  PRM (cm)                                                                           
  0-1.0                    Ref.                                                      
  1.1-3.0                  1.03 (0.37-2.86)    0.949                                 
  3.1-5.0                  0.78 (0.29-2.15)    0.633                                 
  \> 5.0                   0.84 (0.31-2.29)    0.734                                 

PRM: Proximal resection margin; RYGJ: Roux-en-Y gastrojejunostomy; CLN: Total number of collected lymph nodes; LVi: Lymphovascular invasion; PNi: Perineural invasion.

###### 

Analysis of the risk factors associated with recurrence-free survival in patients who underwent total gastrectomy using the Cox proportional hazard model

                           **Univariate**     **Multivariate**                      
  ------------------------ ------------------ ------------------ ------------------ ----------
  Age                      1.01 (1.00-1.02)   0.071              1.01 (1.00-1.02)   0.032
  Female sex               1.23 (0.95-1.56)   0.118                                 
  BMI                      0.96 (0.92-1.00)   0.067                                 
  Tumor location                                                                    
  Upper 1/3                Ref.                                                     
  Mid 1/3                  0.67 (0.51-0.87)   0.002                                 
  Lower 1/3                0.86 (0.57-1.30)   0.859                                 
  Tumor size               1.11 (1.08-1.14)   \< 0.001           1.03 (1.00-1.07)   0.075
  Borrmann type IV         2.84 (2.10-3.83)   \< 0.001           1.91 (1.32-2.76)   0.001
  CLN                      1.00 (0.99-1.01)   0.612                                 
  T stage                                                                           
  T2                       Ref.                                  Ref.               
  T3                       2.20 (1.36-3.54)   0.001              1.31 (0.90-2.16)   0.289
  T4                       4.18 (2.60-6.72)   \< 0.001           1.90 (1.14-3.18)   0.014
  N stage                                                                           
  N0                       Ref.                                  Ref.               
  N1                       1.43 (0.89-2.31)   0.139              1.27 (0.77-2.07)   0.348
  N2                       2.35 (1.55-3.56)   \< 0.001           1.68 (1.06-2.65)   0.026
  N3                       4.90 (3.43-6.99)   \< 0.001           2.84 (1.87-4.32)   \< 0.001
  Diffuse type histology   1.14 (0.86-1.50)   0.357                                 
  LVi                      2.41 (1.84-3.15)   \< 0.001           1.44 (1.08-1.91)   0.013
  PNi                      1.71 (1.33-2.21)   \< 0.001                              
  PRM (cm)                                                                          
  0-1.0                    Ref.                                                     
  1.1-3.0                  0.80 (0.55-1.15)   0.225                                 
  3.1-5.0                  0.63 (0.42-0.95)   0.028                                 
  \> 5.0                   0.74 (0.51-1.07)   0.104                                 

PRM: Proximal resection margin; RYGJ: Roux-en-Y gastrojejunostomy; CLN: total number of collected lymph nodes; LVi: Lymphovascular invasion; PNi: Perineural invasion.

DISCUSSION
==========

It is widely accepted that sufficient resection margins should be achieved for curative resection of gastric cancer. The optimal length for the proximal margin is often suggested to be at least 4-6 cm\[[@B8]-[@B10]\]. Over the years, surgical skills and technologies have developed and fields of minimal, less invasive approaches are quickly growing. Guidelines suggest laparoscopic gastrectomy should be performed for early gastric cancer (EGC) in the distal third of the stomach\[[@B9]\] and laparoscopic TG was recently demonstrated to be safe and feasible for EGC. Moreover, there are ongoing trials and studies for laparoscopic approaches in advanced cancer, particularly in eastern countries. However, surgeons still abide by conventional rules and try to achieve the recommended margin length, even in difficult conditions.

Several studies are rooted in this discrepancy in the appropriate PRM distance. In 2006, Ha et al\[[@B19]\] reported that PRM had no significant influence on the prognosis of EGC patients; however, a PRM length of \> 3 cm improved the survival rates in AGC patients. Squires et al\[[@B15]\] reported their findings from a 2015 study based on 465 patients who underwent curative-intent gastrectomy for distal gastric cancer. Their results indicated that a proximal margin distance \> 3 cm is associated with better OS and RFS in stage I disease, whereas the proximal margin distance did not significantly improve prognosis in either stage II or III disease. The authors concluded that a proximal margin of \> 3 cm is optimal for distal gastric cancer. Wang et al\[[@B12]\] reported that a proximal margin of 2.1-4.0 cm and 4.1-6.0 cm should be obtained for patients with solitary- and infiltrative-type tumors, respectively, for better prognoses. In 2017, based on 974 patients with gastric and esophago-gastric junction cancer, Bissolati et al\[[@B17]\] reported that a resection margin, either proximal or distal, that is \< 2 cm for T1 cancer and \< 3 cm for T2-4 cancer is associated with resection margin involvement, which was demonstrated in previous literature to have a negative prognostic impact\[[@B20]-[@B24]\]. However, Kim et al\[[@B13]\] reported in 2014 that the length of the proximal margin did not affect the OS or local recurrence and several subsequent studies have arrived at similar conclusions\[[@B11],[@B14],[@B18]\].

The conclusions regarding the safe length of PRM, particularly for AGC patients, are not consistent even among recent papers. Thus, we designed a large-scale study to determine the optimal length of the PRM for patients with AGC. Cross-tabulation analysis with our data showed that the incidence of recurrence or local recurrence according to the distance of the PRM did not differ (*P* \> 0.05) in patients who underwent DG or TG for AGC. We performed Kaplan-Meier survival analysis to assess the effect of the PRM distance on RFS and our results showed no statistical difference in RFS between the PRM subgroups. Multivariate analysis using the Cox proportional hazard model revealed consistent results. Although previous reports do not agree on the safety of short resection margins, particularly in AGC, our results demonstrate that the distance of the PRM did not affect the prognosis of AGC patients who underwent curative gastrectomy.

Our multivariate analysis of influential factors in RFS and OS for patients who underwent DG showed significant differences between different reconstruction methods; this is inconsistent with previous literature. Billroth I was the most preferred reconstruction method after gastrectomy for gastric cancer patients at our institution. When a tumor involved pylorus or the stomach stump was too short for gastroduodenostomy, Billroth II or RYGJ was applied. Therefore, there is a chance that cases with B-II and RYGJ anastomosis were associated with larger and more progressed tumors. Another possible reason is that because Billroth I is the most preferred method in our institution, surgeons were more comfortable with the procedure, resulting in better outcomes. Although there is no consensus, a number of studies reveal more gastric stump cancer in patients who underwent Billroth II reconstruction rather than Billroth I after gastrectomy either due to carcinoma or benign lesions\[[@B25]-[@B27]\]. There is also an RCT from Japan that shows more hematogenous recurrence in B-II compared to B-I\[[@B28]\]. This is an important result that warrants further investigation with a careful design, taking many factors such as recurrence patterns, recurred time after surgery, histology of the initial tumor, and many other factors into consideration.

There is a limitation in the retrospective design of this study. Another limitation is that the length of the resection margin used in the study may not accurately portray the gross distance we observe intraoperatively. We used the PRM as described on the pathologic report, which was measured under formalin fixation. We chose to use the pathologic report because measurements from the operation room are expected to be less consistent depending on the measured time after resection or in cases with indistinctive tumor margins such as linitis plastica. Additionally, for TG, we used circular staplers that produce doughnut specimens that are not added to the length of PRM, so the actual PRM may be few millimeters longer than measured.

In conclusion, the distance of PRM is not a prognostic factor for AGC patients; it does not affect the incidence of recurrence or local recurrence. A greater PRM distance was not associated with better survival outcomes and a distance of \< 1 cm did not correlate with worse OS or RFS.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The conventional guidelines suggest the surgeons to obtain an extensive resection margin during surgery for gastric cancer. Several recent studies have raised questions regarding the need for such extensive resection and necessity of total gastrectomy for tumors located on middle-third of stomach, while the consensus has not been reached. There are some studies those demonstrate the unnecessity of longer proximal resection margin (PRM) distance in early gastric cancer. However, there are very few regarding the PRM distance for advanced gastric cancer (AGC).

Research motivation
-------------------

We would like to discover the optimal PRM distance for patients who undergo gastrectomy for AGC.

Research objectives
-------------------

The objective of this study was to investigate the influence of the PRM distance on the oncologic outcomes of patients who underwent gastrectomy for AGC, thus to prove the safety of the PRM distance shorter than the conventional literatures suggest.

Research methods
----------------

We retrospectively collected data from 1518 patients who underwent total gastrectomy (TG) or distal gastrectomy (DG) for AGC between June 2004 and December 2007. The distances of the PRM and DRM were defined as the shortest distance from the most proximal or distal end to each resection line, measured on formalin-fixed surgical specimens by pathologists. The demographics and clinicopathologic outcomes were compared according to the different PRM categories and an analysis on the influence of PRM on recurrence-free survival and overall survival was performed.

Research results
----------------

The DG and TG groups showed no statistical difference in RFS or OS according to the distance of PRM. Multivariate analysis also revealed that in both groups, there was no significant difference in RFS or OS according to the PRM distance.

Research conclusions
--------------------

The distance of PRM did not affect the incidence of recurrence or local recurrence. A greater PRM distance was not associated with better survival outcomes and a distance as short as \< 1 cm did not correlate with worse OS or RFS. Therefore, the PRM distance shorter than conventional literatures suggest may be accepted.

Research perspectives
---------------------

Further research would be essential to set a guideline for the optimal PRM distance for AGC. A long-term prospective study with detailed data on PRM including measurements done during operation by the surgeons and after fixation by the pathologists should give better answers.
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